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Abstract
Background—During the 2014–15 US influenza season, expanded genetic characterization of 
circulating influenza A(H3N2) viruses was used to assess the impact of genetic variability of 
influenza A(H3N2) viruses on influenza vaccine effectiveness (VE).
Methods—A novel pyrosequencing assay was used to determine genetic group based on 
hemagglutinin (HA) gene sequences of influenza A(H3N2) viruses from patients enrolled US Flu 
Vaccine Effectiveness network sites. Vaccine effectiveness was estimated using a test-negative 
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design comparing vaccination among patients infected with influenza A(H3N2) viruses and 
uninfected patients.
Results—Among 9710 enrollees, 1868 (19%) tested positive for influenza A(H3N2); genetic 
characterization of 1397 viruses showed 1134 (81%) belonged to one HA genetic group (3C.2a) of 
antigenically drifted H3N2 viruses. Effectiveness of 2014–15 influenza vaccination varied by 
A(H3N2) genetic group from 1% (95% confidence interval [CI], −14% to 14%) against illness 
caused by antigenically drifted A(H3N2) group 3C.2a viruses versus 44% (95% CI, 16% to 63%) 
against illness caused by vaccine-like A(H3N2) group 3C.3b viruses.
Conclusion—Effectiveness of 2014–15 influenza vaccination varied by genetic group of 
influenza A(H3N2) virus. Changes in hemagglutinin genes related to antigenic drift were 
associated with reduced vaccine effectiveness.
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INTRODUCTION
The 2014–2015 influenza season was characterized by widespread circulation of influenza 
A(H3N2) viruses, with high levels of outpatient illness and influenza-associated 
hospitalization, especially for adults aged ≥65 years [1]. Characterization of influenza 
A(H3N2) viruses that circulated in the US indicated that the majority were antigenically 
different (drifted) from the A(H3N2) vaccine component of 2014–2015 Northern 
Hemisphere seasonal influenza vaccines [2]. Antigenic relatedness of vaccine strains and 
circulating viruses is traditionally determined by the hemagglutination inhibition (HI) assay, 
which measures inhibition of virus-mediated agglutination of red blood cells by reference 
antisera from ferrets inoculated with vaccine viruses [3]. During the 2014–15 season, 
changes in the properties of many A(H3N2) viruses resulted in insufficient hemagglutination 
activity for characterization by HI [1]. In response, sequencing of hemagglutinin (HA) genes 
was increasingly used to determine genetic relatedness of antigenic variates of influenza 
A(H3N2) viruses [4]. Few studies have evaluated differences in influenza vaccine 
effectiveness according to genetic relatedness among influenza viruses [5, 6].
The multisite US Flu Vaccine Effectiveness network estimates influenza vaccine 
effectiveness (VE) each season; interim estimates of VE were 23% (95% confidence interval 
[CI] = 8%–36%) among patients enrolled November 10, 2014—January 2, 2015 when most 
influenza illnesses were due to A(H3N2) viruses [7]. To improve our ability to characterize 
the effect of antigenically drifted A(H3N2) viruses on influenza VE, we used a newly 
developed, high throughput pyrosequencing assay (unpublished data) to genetically 
characterize A(H3N2) viruses directly from respiratory specimens collected from patients 
enrolled in the Flu VE study. We report VE for the most common H3N2 genetic groups 
circulating in the US during 2014–15, and for the subset of A(H3N2) viruses that could not 
be genetically characterized. In addition, to better understand the genetic variability and 
geographic and temporal distribution of circulating A(H3N2) viruses in the United States 
Flannery et al. Page 2
J Infect Dis. Author manuscript; available in PMC 2018 February 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
during 2014–15, we describe the A(H3N2) genetic groups among U.S. surveillance viruses 
during the 2014–2015 influenza season.
MATERIALS AND METHODS
US Flu VE Network
US Flu VE network methods have been previously described.[8–10] Briefly, patients aged 
≥6 months seeking outpatient medical care for an acute respiratory illness (ARI) within 7 
days of illness onset were enrolled at study sites in Michigan, Pennsylvania, Texas, 
Washington, and Wisconsin during periods of influenza virus circulation at each site. 
Presence of a high-risk medical condition was defined as documentation of any International 
Classification of Diseases, Ninth Revision (ICD-9) diagnostic code associated with specified 
high-risk conditions[11] in the patient’s medical record during the 12 months before 
enrollment. Receipt of 2014–2015 influenza vaccine was confirmed by review of medical 
records or immunization registries; patients who self-reported vaccination not captured by 
medical records or registries were assumed to be vaccinated if plausible information on date 
and location of vaccine receipt was provided. Receipt of prior season (2013–2014) influenza 
vaccine was obtained from medical records or immunization registries only. We excluded 
patients vaccinated 0–13 days before illness onset and those aged 6 months to 8 years who 
received only one dose of 2014–2015 influenza vaccine for whom two doses were 
recommended by the Advisory Committee on Immunization Practices (ACIP).[11]
Respiratory specimens (combined nasal and oropharyngeal swabs for patients aged ≥2 years; 
nasal swabs only for patients aged 6–23 months) were collected and tested for influenza 
viruses at Flu VE network laboratories by rRT-PCR.[12] A subset of influenza-positive 
specimens from each network site, including the first 10 positive specimens identified and 
up to five positive specimens every two weeks during the enrollment period, were sent to 
National Influenza Surveillance Reference Centers for virus isolation and propagation for 
antigenic characterization by HI. Given challenges with antigenic characterization of many 
A(H3N2) viruses, A(H3N2)-positive respiratory specimens containing high levels of 
influenza virus RNA (defined as rRT-PCR cycle threshold value ≤ 30) were sent to CDC for 
pyrosequencing directly from respiratory specimens. All A(H3N2)-positive specimens from 
the Pennsylvania Flu VE site were processed by pyrosequencing as, in contrast to other 
locations, early testing suggested widespread circulation of vaccine-like strains.
Virologic Surveillance
Distribution of influenza A(H3N2) viruses in the United States before and during the 2014–
15 influenza season was examined using virologic surveillance data for influenza A(H3N2) 
viruses identified by U.S. public health laboratories from March 1, 2014 through April 10, 
2015 and submitted to CDC for virus characterization. CDC requested that state public 
health laboratories submit the first ten influenza-positive specimens of any virus type or 
subtype and up to five positive specimens every two weeks throughout the season to CDC. 
For A(H3N2) viruses that did not achieve sufficient hemagglutination titers for antigenic 
characterization by HI, genetic characterization was used to determine HA genetic group 
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and antigenic properties were inferred based on the subset of viruses from the same HA 
genetic group that could be characterized by HI assays.[1]
Genetic characterization
Analyses of full-length HA sequences from influenza A(H3N2) viruses collected from 
January 1 through December 1, 2014, and characterized at CDC were used to design a high-
throughput pyrosequencing assay to screen A(H3N2) viruses for genetic markers associated 
with six major HA genetic groups (3C.2, 3C.2a, 3C.2b, 3C.3, 3C.3a, and 3C.3b). Viral RNA 
was extracted from clinical specimens in a 96-well plate format using MagNA Pure 96 
nucleic acid isolation system (Roche Diagnostics, Basel, Switzerland). A fragment of the 
HA1 coding region, encompassing nucleotides 370 to 645, was amplified using RT-PCR and 
subjected to sequence analysis using a PyroMark Q96ID sequencing platform (Qiagen, 
Valencia, CA), essentially as described.[13] Three pyrosequencing primers were utilized to 
generate pyrograms for three target HA regions encompassing the following nucleotides: (1) 
412–431; (2) 456–481; and (3) 559–571. Sequencing results were analyzed using IdentiFire 
software (Qiagen, Valencia, CA) and a purpose-built library containing the signature 
sequences of target regions. Unique combination of short signature sequences within each 
target region allows identification of 3C.2, 3C.2a, 3C.2b, 3C.3, 3C.3a, and 3C.3b clades 
(Protocol for the pyrosequencing assay is available upon request, Email: 
fluantiviral@cdc.gov).
In addition, for a subset of viruses, full-length HA sequences were obtained from whole 
genome sequencing, performed as previously described.[14] Sequence data were deposited 
to the Global Initiative on Sharing All Influenza Data (GISAID). A(H3N2) viruses were 
classified into previously described HA genetic groups based on phylogenetic analysis.[15]
2014–2015 vaccine components and genetic groups
The A(H3N2) reference virus for 2014–2015 Northern Hemisphere influenza vaccines was 
A/Texas/50/2012(H3N2), HA genetic group 3C.1. For antigenic characterization of 
circulating A(H3N2) viruses, CDC used a panel of ferret antisera raised against egg- and 
cell-propagated reference viruses including A/Texas/50/2012, A/Michigan/15/2014 (group 
3C.2a), A/Louisiana/39/2013 (group 3C.2b), A/New York/39/2012 (group 3C.3), A/
Pennsylvania/09/2015 (group 3C.3b) and A/Switzerland/9715293/2013 (group 3C.3a), the 
A(H3N2) reference virus for 2015–2016 Northern Hemisphere vaccines.
Vaccine effectiveness
Among all patients enrolled in the Flu VE network study, we compared characteristics of 
patients with genetically characterized A(H3N2) virus infection and all A(H3N2)-positive 
patients to influenza-negative patients, excluding patients infected with other influenza 
viruses. We tested statistical significance of differences with the χ2 test for categorical, and 
the Wilcoxon Mann-Whitney test for continuous variables. Influenza VE was estimated 
using a test-negative design,[16, 17] which compares the odds of 2014–2015 influenza 
vaccine receipt among A(H3N2)-positive patients (for any A(H3N2) virus and by A(H3N2) 
virus genetic group) with influenza test-negative patients. VE was estimated as 100% × [1 - 
adjusted odds ratios (OR)] from logistic regression models by including network site, patient 
Flannery et al. Page 4
J Infect Dis. Author manuscript; available in PMC 2018 February 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
age, presence of high-risk medical condition and calendar time as previously described;[9] 
addition of sex, race/Hispanic ethnicity and days from illness onset to specimen collection 
did not change the adjusted OR by ≥5%, the pre-determined threshold for inclusion in the 
model.[9] Logistic regression models for patients aged ≥6 months included patient age (in 
years, modeled using linear tail-restricted cubic spline functions with 5 knots based on 
percentiles); models for specific age categories included patient’s age in years. We assessed 
potential effect modification by prior season (2013–2014) vaccination status by including 
main effects and an interaction term for current and prior season vaccination in logistic 
regression models.[10] Additional analyses were conducted restricting patients to those 
enrolled within 4 days of symptom onset and using an expanded group of patients that 
included partially vaccinated children. All reported tests were 2-sided and a p-value <0.05 
was considered statistically significant; VE was considered statistically significant if 95% 
confidence intervals (CI) excluded zero. Statistical analyses were conducted using SAS for 
Windows (version 9.3, Cary, NC).
RESULTS
At US Flu VE network sites, 9710 patients aged ≥ 6 months with ARI were enrolled during 
periods of influenza virus circulation from November 10, 2014 through April 10, 2015; 1868 
(19%) patients tested positive for A(H3N2), while 7390 (75%) patients tested negative for 
influenza. In addition, 4 (<1%) patients were infected with influenza A(H1N1)pdm09 virus 
and 399 (4%) with influenza B viruses, including two patients co-infected with A(H3N2) 
and B viruses. VE against influenza B viruses will be published separately.
Genetic group was determined by pyrosequencing assay for 1397 (95%) of 1464 A(H3N2)-
positive US Flu VE patient specimens selected for genetic characterization at CDC (78% of 
all A(H3N2)-positive cases). Proportions of patients for whom A(H3N2) genetic group was 
determined differed by study site, age, race/Hispanic ethnicity and self-rated illness severity 
(p<0.05), but were similar by vaccination status (Supplementary eTable 1). For 138 
specimens characterized by complete HA sequencing and pyrosequencing, results were 
100% concordant. A(H3N2) genetic group 3C.2a viruses predominated, accounting for 1134 
(81%) of 1397 genetically characterized A(H3N2) viruses from Flu VE network sites. 
Compared to the 2014–2015 vaccine reference virus A/Texas/50/2012 (group 3C.1; Figure 
1), HA sequences from group 3C.2a viruses shared an amino acid change from 
phenylalanine to tyrosine at position 159 (F159Y), which has been associated with reduced 
inhibition by ferret antisera raised against the vaccine virus. Of 35 A(H3N2) group 3C.2a 
viruses from the Flu VE network study characterized by HI, 31 (89%) were poorly inhibited 
by ferret antisera against the A/Texas/50/2012 vaccine reference virus, in agreement with 
data from US virologic surveillance (Supplementary eTable 2). Among other A(H3N2) 
viruses from Flu VE patients, 56 (4%) A(H3N2) viruses belonged to the antigenically 
drifted genetic group 3C.3a, 48 (3%) to vaccine-like group 3C.3 and 159 (11%) to group 3C.
3b. Group 3C.3a viruses, including the 2015–16 A(H3N2) vaccine reference virus A/
Switzerland/9715293/2013, had a parallel amino acid substitution to group 3C.2a viruses at 
position 159 (phenylalanine to serine [F159S]), but were considered antigenically similar to 
group 3C.2a viruses by HI.[18] Group 3C.3b viruses included an amino acid change from 
lysine to serine at position 157 (L157S) that was not associated with antigenic drift: 10 
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(63%) of 16 A(H3N2) group 3C.3b viruses from Flu VE patients were considered 
antigenically similar to A/Texas/50/2012 by HI, similar to proportions observed among US 
surveillance isolates (Supplementary eTable 2).
Prior to the enrollment period at Flu VE network sites, the proportion of influenza A(H3N2) 
viruses submitted to CDC from US surveillance laboratories that belonged to HA group 3C.
2a increased from 38% (of 92 viruses characterized) in March 2014 to 73% (of 327) in 
November, 2014. At Flu VE sites, the proportion of group 3C.2a viruses increased during 
the 2014–15 season; peak numbers of group 3C.2a-positive patients were enrolled in 
December, corresponding to peak case enrollment (Figure 2). While group 3C.2a viruses 
predominated, distribution of genetic group varied by Flu VE network site (Figure 3A), with 
greater circulation of vaccine-like strains at the Pennsylvania site. Similar variability in the 
geographic distribution of HA genetic group was observed among influenza A(H3N2) 
viruses collected by US public health laboratories during November, 2014—April, 2015 
(Figure 3B).
Vaccine effectiveness
A total of 1817 A(H3N2)-positive patients and 7079 influenza test-negative patients from 
the Flu VE network study contributed to VE estimates (Table 1), after excluding influenza B 
positive patients (n=399), incompletely vaccinated patients aged 6 months to 8 years 
(n=175), patients vaccinated 0–13 days before illness onset (n=149), and influenza test-
negative patients (n=40) with illness onset outside the period when influenza cases were 
identified at each study site. Compared with influenza test-negative patients, higher 
percentages of A(H3N2)-positive patients were aged ≥65 years, White non-Hispanic, 
reported excellent or very good general health, enrolled within two days of illness onset and 
reported feverishness during current illness. Influenza test-negative patients were more likely 
to report cigarette smoking or household exposure to smoke, and to live in households with 
≥1 child aged <12 years.
In all, 4811 patients (54%) included in the analysis had received 2014–2015 influenza 
vaccine, including 939 (52%) of 1817 A(H3N2)-positive patients and 3866 (55%) of 7078 
influenza-negative patients; VE against A(H3N2)-associated illness was 7% (95% CI, −5% 
to 17%) (Table 2). Estimated VE against A(H3N2)-associated illness was 14% (95% CI, 
−3% to 28%) among patients enrolled prior to January 2, 2015 and −2% (95% CI, −20% to 
14%) among those enrolled after January 2, 2015.
VE estimates were similar when restricted to 1359 infections with genetically characterized 
A(H3N2) viruses (6% [95% CI, −7% to 18%]) or 458 infections with uncharacterized 
A(H3N2) viruses (11% [95% CI, −10 to 27]), but differed by HA genetic group. Among all 
patients aged ≥6 months, estimated VE against illness due to infection with HA genetic 
group 3C.2a viruses was 1% (95% CI, −14% to 14%]) versus 44% (95% CI, 16% to 63%) 
against illness due to group 3C.3b viruses (Table 2). Among patients infected with viruses 
from HA genetic groups 3C.3 or 3C.3a, VE estimates were not statistically significant. No 
statistically significant interaction was observed between current (2014–2015) and prior 
(2013–14) season vaccination status, for any A(H3N2)-related illness or for genetic groups 
of A(H3N2) viruses. Inclusion of partially vaccinated children and restriction of analysis to 
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patients enrolled within four days of symptom onset resulted in similar VE estimates (data 
not shown).
DISCUSSION
The 2014–2015 influenza season in the United States was notable for the early and 
widespread circulation of A(H3N2) viruses, the majority of which belonged to an emergent 
HA genetic group 3C.2a and showed substantial antigenic drift from the A(H3N2) 
component of 2014–2015 Northern Hemisphere seasonal influenza vaccines.[1] Expanded 
genetic characterization of A(H3N2) viruses from surveillance sites in the United States 
identified variability in geographic and temporal distribution of genetic groups of A(H3N2) 
viruses. Development of a pyrosequencing assay, with high throughput, provided genetic 
group information on a large number of influenza A(H3N2) viruses from US Flu VE 
network sites, permitting strain-specific estimates that revealed differences in VE caused by 
specific HA genetic groups of A(H3N2) viruses. Low VE against genetic group 3C.2a 
viruses was consistent with antigenic drift. Low or null effectiveness for 2014–2015 
influenza vaccines against influenza A(H3N2)-associated illness was also reported in mid-
season estimates from other surveillance networks in which A(H3N2) group 3C.2a viruses 
predominated, including networks in Canada[19] and the United Kingdom.[20] In contrast, 
we found evidence of modest (44%) VE against A(H3N2) viruses in group 3C.3b, which 
were characterized as antigenically similar to the 2014–2015 vaccine reference virus A/
Texas/50/2012. Viruses from the 3C.3b genetic group appeared to be more common in some 
regions of the country, including the Pennsylvania Flu VE network site. Although 
vaccination provided some protection against A(H3N2) viruses belonging to group 3C.3b, 
the predominance of the drifted 3C.2a viruses in the United States resulted in low overall VE 
against medically attended influenza-associated illness during the 2014–2015 season.[21]
Differences in VE have been observed during seasons with mixed circulation of viruses 
antigenically matched and mismatched to vaccine components,[22, 23] with the 2014–2015 
season having a very high proportion of circulating A(H3N2) viruses that were antigenically 
mismatched to the vaccine. During seasons in which antigenically drifted viruses circulate, 
VE has not consistently been associated with the degree of antigenic similarity as measured 
by the HI assay.[23] The addition of genetic characterization of a large number of A(H3N2) 
viruses from patients enrolled in the Flu VE network study during the 2014–2015 season 
provided the opportunity to examine differences in VE by genetic group. This analysis 
suggests that protection against A(H3N2) viruses may be related to vaccine protection 
against specific virus genetic groups and the distribution of those viruses in the community. 
In addition, genetic characterization of A(H3N2) viruses from US laboratories provided 
insight into the rapid spread of antigenically mismatched viruses from a single genetic 
group, as well as local variability in the distribution of HA genetic groups antigenically 
matched to vaccine. Genetic data also provided better representation of antigenic mismatch 
between vaccine and circulating A(H3N2) viruses, many of which could not be 
characterized using the HI assay. In the future, studies to assess VE against distinct groups 
of influenza viruses may augment data from traditional methods to identify potential vaccine 
candidates and ultimately lead to improved vaccines.[24]
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The 2014–2015 influenza season highlighted challenges with formulation of influenza 
vaccines that require frequent updates due to rapid changes in circulating viruses, as well as 
limitations inherent in the current methods to select vaccine virus candidates. In February 
2014 at the time of virus strain selection for 2014–2015 Northern Hemisphere vaccines, 
greater than 90% of characterized A(H3N2) viruses were found to be antigenically similar to 
the 2013–2014 vaccine reference virus, A/Texas/50/2012.[15] WHO recommended no 
change in the A(H3N2) vaccine strain for the 2014–2015 season.[15] In March, 2014, after 
the 2014–15 vaccine strain had been selected, antigenic drift variants belonging to HA 
genetic groups 3C.3a and 3C.2a were detected. During May–September, 2014, the 
proportion of these drift variants increased rapidly with a predominance of HA genetic 
group 3C.2a viruses in the United States, and fewer than 50% of A(H3N2) viruses 
characterized by HI were inhibited by ferret reference antisera against A/Texas/50/2012.[25] 
These virologic findings together with epidemiologic and human serology data resulted in a 
change in recommended A(H3N2) vaccine component to an A/Switzerland/9715293/2013-
like virus from HA group 3C.3a for the 2015 Southern Hemisphere season.[18]
Results from the US Flu VE network indicated that differences in vaccine effectiveness may 
have resulted from a small degree of genetic change associated with substantial antigenic 
differences within related HA genetic groups of A(H3N2) viruses. Amino acid substitutions 
at specific HA antigenic sites have been associated with major antigenic changes (referred to 
as cluster transitions) in A(H3N2) viruses since their emergence in humans in 1968.[26] 
A(H3N2) genetic group 3C.2a viruses possessed multiple amino acids changes in HA 
relative to the A/Texas/50/2012 reference vaccine virus, including the F159Y change near 
the receptor binding site.[27] In addition, the majority of viruses in HA genetic group 3C.2a 
contain an amino acid substitution at residue 160 that adds a glycosylation site at residues 
158–160, which may shield antigenic sites from neutralizing antibodies.[28] Interestingly, 
A(H3N2) genetic group 3C.3a viruses, including the 2015–2016 Northern Hemisphere 
vaccine reference virus A/Switzerland/9715293/2013, contain a different amino acid at 
residue 159 that nonetheless may have resulted in similar antigenic properties to 3C.2a 
viruses.[18] In contrast, HA genetic group 3C.3b viruses, which do not have antigenically 
important amino acid substitutions like that at residue 159 were characterized as 
antigenically similar to A/Texas/50/2012, consistent with the observation of modest VE. 
Small numbers of infections with HA group 3C.3 and 3C.3a viruses limited our ability to 
estimate VE against illness due to these genetic groups. From October 4—November 28, 
2015, the majority of 3C.2a viruses characterized were well inhibited by ferret reference 
antisera raised against A/Switzerland/9715293/2013, indicating better antigenic match 
between 2015–2016 vaccine and circulating A(H3N2) viruses.[29] However, the 
effectiveness of influenza vaccines against circulating A(H3N2) viruses will need to be 
monitored closely because of the likelihood of continuing drift among circulating strains.
Our results are subject to several limitations. Influenza A(H3N2)-positive specimens from 
study participants submitted for characterization had lower rRT-PCR cycle threshold values 
possibly corresponding with higher viral load [30]. Antigenic properties were inferred from 
a subset of viruses characterized by HI. However, antigenic characterization of viruses from 
the US Flu VE network agreed with virologic surveillance data. Secondly, the validity of the 
test-negative design depends upon accurate classification of influenza status.[31] In addition 
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to the use of the highly specific rRT-PCR assay, patients in the US Flu VE network study 
were enrolled within 7 days of illness onset when viral shedding was highest, decreasing the 
likelihood of false negative results. Lastly, patients at higher risk of influenza-related illness 
have higher rates of influenza vaccination; while estimates adjust for potential confounding 
variables, residual confounding may bias estimates. However, the test-negative design, by 
testing patients presenting for care, reduces potential selection bias related to care-seeking 
behavior.[16, 17]
During 2014–15, several genetically related influenza A(H3N2) viruses circulated in the US 
but one group predominated over time. We found that influenza vaccination in 2014–2015 
did not reduce the likelihood of influenza illness caused by the predominant genetic group of 
A(H3N2) viruses, but prevented some disease due to A(H3N2) viruses in less prevalent 
genetic groups.[21] Overall low effectiveness of influenza vaccines may have contributed to 
high rates of influenza-associated hospitalizations observed during the season[1] despite 
vaccination of approximately two-thirds of the US population aged ≥65 years.[32] Expanded 
availability of high-throughput platforms for nucleotide sequencing and genetic 
characterization of larger numbers of influenza viruses may provide more complete and 
timely information on emergent influenza viruses to inform vaccine strain selection and help 
evaluate protection provided by vaccination.
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Figure 1. Phylogenetic tree based on hemagglutinin (HA) genes of influenza A(H3N2) viruses 
collected during March, 2014–April, 2015 and analyzed at CDC
Phylogenetic tree is based on genetic differences compared to A/Texas/50/2012 consensus 
sequence. Amino acid substitutions delineating major branches are shown. Date of 
collection follows names of viruses from U.S. public health laboratories participating in U.S. 
virologic surveillance (normal font) and from patients enrolled at US Flu Vaccine 
Effectiveness network sites (bold font).
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Figure 2. 
Numbers of PCR-confirmed infections with influenza A(H3N2) viruses by genetic group 
and percent influenza positivity among patients with medically-attended acute respiratory 
illness, by week of symptom onset, US Flu Vaccine Effectiveness Network, United States, 
November 10, 2014—April 10, 2015.
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Figure 3. Geographic distribution of genetic groups of influenza A(H3N2) viruses in the United 
States and from patients enrolled in the US Flu Vaccine Effectiveness study
3A: Viruses from influenza A(H3N2)-positive patients enrolled from November 10, 2014 
through April 10, 2015 (n=1397). Pie charts present the proportional distribution of HA 
genetic group, based on the number of genetically characterized influenza A(H3N2) viruses 
from patients enrolled at each study site.
3B: Viruses identified by U.S. public health laboratories from November 10, 2014 through 
April 10, 2015 and submitted to CDC for genetic characterization (n=1633). Pie charts 
present the proportional distribution of HA genetic group, based on the number of 
genetically characterized influenza A(H3N2) viruses from each state or territory.
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Table 1
Characteristics of patients enrolled in the US Flu Vaccine Effectiveness network study, by influenza RT-PCR 
resulta
Genetically 
characterized 
influenza A(H3N2)-
positive cases 
(N=1397)
All influenza 
A(H3N2)-
positive cases 
(N=1817) Influenza-negative controls (N=7078) P-valueb
n (col %) n (col %) n (col %)
Site <.001
 Michigan 201 (14.4) 307 (16.9) 1152 (16.3)
 Pennsylvania 382 (27.3) 424 (23.3) 1024 (14.5)
 Texas 191 (13.7) 280 (15.4) 1318 (18.6)
 Washington 317 (22.7) 416 (22.9) 2272 (32.1)
 Wisconsin 306 (21.9) 390 (21.5) 1312 (18.5)
Age <.001
 6 mo–8 y 327 (23.4) 396 (21.8) 1946 (27.5)
 9–17 y 229 (16.4) 306 (16.8) 950 (13.4)
 18–49 y 389 (27.9) 531 (29.2) 2206 (31.2)
 50–64 y 205 (14.7) 281 (15.5) 1118 (15.8)
 ≥ 65 y 247 (17.7) 303 (16.7) 858 (12.1)
Male sex 601 (43.0) 767 (42.2) 2969 (42.0) 0.84
Race/ethnicity <.001
 White, non-Hispanic 1081 (77.7) 1397 (77.1) 5182 (73.4)
 Black, non-Hispanic 108 (7.8) 133 (7.3) 552 (7.4)
 Hispanic 82 (5.9) 119 (6.6) 685 (9.7)
 Other, non-Hispanic 120 (8.6) 162 (9.0) 673 (9.5)
Any high-risk condition 521 (37.3) 671 (36.9) 2636 (37.2) 0.81
Interval from onset to specimen 
collection
<.001
 0–2 d 698 (50.0) 839 (46.2) 1904 (26.9)
 3–4 d 488 (35.0) 638 (35.1) 2771 (39.1)
 5–7 d 211 (15.1) 340 (18.7) 2403 (34.0)
Reported general health statusc 0.01
 Excellent/very good 1026 (76.1) 1342 (74.2) 4991 (70.6)
 Good 282 (20.3) 368 (20.3) 1639 (23.2)
 Fair/poor 83 (6.0) 99 (5.5) 442 (6.3)
Self/household exposure to smokec 176 (12.6) 229 (12.6) 1248 (17.7) <.001
≥1 child <12 years of age in householdc 522(37.6) 708 (39.0) 2828 (40.0) 0.30
Reported fever 1132 (81.2) 1459 (80.4) 3876 (54.9) <.001
Reported current health assessment 
score, median (IQR)d
50 (40–70) 50 (40–70) 60 (45–75) <.001
Vaccination status 2014–2015 0.03
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Genetically 
characterized 
influenza A(H3N2)-
positive cases 
(N=1397)
All influenza 
A(H3N2)-
positive cases 
(N=1817) Influenza-negative controls (N=7078) P-valueb
n (col %) n (col %) n (col %)
≥1 doses 749 (53.6) 939 (51.7) 3866 (54.6)
0 doses 648 (46.4) 878 (48.3) 3212 (45.4)
Abbreviation: IQR, interquartile range.
a
Exclusions from total enrollment: influenza A H1N1pdm09-positive (n=4), influenza B-positive (n=397), co-infections with influenza A(H3N2) 
and B viruses (n=2), influenza A-positive of undetermined subtype (n=19), indeterminate influenza rRT-PCR result (n=7).
b
The χ2 statistic was used to assess differences between the numbers of persons with influenza A(H3N2)-positive and influenza-negative test 
results with respect to the distributions of site, age group, sex, race/ethnicity, presence of any high risk condition, interval from illness onset to 
specimen collection, general health status, smoke exposure in self/household, presence of children ages <12 years in the household and vaccination 
status. The Wilcoxon Mann-Whitney test was used to assess differences with respect to the distribution of the current health assessment. A P value 
<.05 is statistically significant.
c
Data were missing for 14 enrollees.
d
Possible values range from 1 (the worst) to 100 (the best). Data were missing for 16 enrollees.
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